MoFo BioMeter - Vol. 3, Issue 2, May 2014 - Early Stage Deals Dominant Q1: Uptick in total dealmaking activity compared with same quarter last year

more+
less-
more+
less-

The MoFo BioMeter for the first quarter of 2014 shows a decrease in average BioMeter value in a quarter dominated by early stage deals. Total dealmaking activity showed an uptick compared to the same quarter in 2013.

In the first quarter of 2014, the average BioMeter value for all transactions was approximately $15.9 million, a decrease compared to the same quarter in 2013. As with the same quarter in 2013, the BioMeter value for the first quarter in 2014 was influenced significantly by a deal by Moderna Therapeutics, this one with Alexion, which had a $100 million up-front payment and covered 10 compounds. Also impacting the results for Q1 was the AnaptysBio/Tesaro transaction for up to three products. If the upfront payments for each of these transactions had been divided by the number of products, the average BioMeter value would have been approximately $10.3 million.

Please see full report below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Biotechnology, Pharmaceutical, Technology

Published In: General Business Updates, Finance & Banking Updates, Science, Computers & Technology Updates, Securities Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »